BRCA1 and neoplasm: Germline assessment alone will miss approximately 7% of patients who harbour somatic BRCA1/2 mutations [20] and tumour testing alone may miss approximately 5% of patients who have germline mutations due to decreased test sensitivity and coverage [46].